Societal and Benuvia Ink Pact To Promote Services To Drug Developers

Benuvia Operations, LLC, a U.S.-based drug developer and manufacturer of active pharmaceutical ingredients (APIs) with specialized expertise in controlled substances (cannabinoids and psychedelics), and Societal CDMO, Inc., a contract development...

Lupin Digital Health Introduces Cardiologist Certificate

Lupin Digital Health, the leading evidence-based digital diagnostics (DTx) platform, and the American College of Cardiology (ACC), the world scientific leader in cardiology, have introduced the world's first Digital Recovery Certification.

Astellas Pharma & Mass General Brigham Collaboration

Astellas Pharma Inc., a pharmaceutical company operating in more than 70 countries worldwide, announced a strategic partnership with Mass General Brigham, focused on translational medicine and early-stage development, to create an integrated approach

FM's Bio-Pharma & Medical College Boost in Interim Budget

In the pre-election budget, which did not mention any changes in direct or indirect taxes, Union Finance Minister Nirmala Seetharaman announced new plans to promote bio-based manufacturing in biomedicine and plans to set up more medical colleges.

Health Canada Approves Xtandi for Non-Metastatic Prostate Cancer

Astellas Pharma Canada, Inc., the Canadian subsidiary of Astellas Pharma Inc. of Tokyo, announced that Health Canada has approved a new drug application for Xtandi (enzalutamide) in the advanced treatment area of prostate cancer.

Stryker introduces Tornier Shoulder Arthroplasty Portfolio in India

Stryker, one of the world’s leading medical technologies companies, has introduced the Tornier shoulder arthroplasty portfolio in India and launched its first new Tornier product, the PerformTM Humeral Stem today at Shoulder Conclave in Pune...

Budget 2024: Contemplating HPV Vaccine for Cervical Cancer – FM

Cancer vaccines will become more expensive after the government considers adding the human papillomavirus (HPV) vaccine to the national immunization program

Piramal Pharma Revenue Rises 14% at Rs 1,959 Crore in Q3

Piramal Pharma Ltd detailed a 14% year-on-year ascend in its united income from tasks to ₹1,959 crore in the December finished quarter (Q3FY24), driven areas of strength for by across its verticals.

Glenmark and Pfizer Partner To Unveil Abrocitinib in India

Glenmark said it has collaborated with Pfizer to send off abrocitinib in India utilized for treatment of moderate-to-extreme atopic dermatitis (Promotion). Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and...

QIAGEN Launches QIAstat-Dx Syndrome Tests in India

QIAGEN has launched two disease test panels for its QIAstat-Dx device in India, including the gastrointestinal panel two and meningitis/encephalitis panel

© 2024 India Pharma Outlook. All Rights Reserved.